Vaccination in pregnancy against pertussis: A consensus statement on behalf of the global pertussis initiative
Vaccination in pregnancy against pertussis: A consensus statement on behalf of the global pertussis initiative
Vaccination against pertussis in pregnancy is safe for pregnant women and newborns. Vaccination against pertussis during the second or early third trimester of pregnancy is highly protective against pertussis in young infants. Vaccination early in the third trimester versus vaccination late in the third trimester is associated with higher newborn anti-B. pertussis antibody levels. Infants whose mothers were vaccinated in pregnancy have less boosting of anti-B. pertussis antibody concentrations after their own vaccination, but this is not clinically significant. More immunogenicity and vaccine effectiveness studies are needed in countries using whole-cell pertussis vaccines. Vaccination in pregnancy induces anti-B. pertussis antibodies in breast milk. COVID-19 mitigation strategies have resulted in a significant decrease in B. pertussis circulation, which could negatively affect population immunity against B. pertussis. Highlights: Infants are at high risk for severe morbidity and mortality from pertussis disease during early infancy. Vaccination against pertussis in pregnancy has emerged as the ideal strategy to protect infants during these early, vulnerable, first months of life. On 30 November and 1 December 2021, the Global Pertussis Initiative held a meeting that aimed to discuss and review the most up-to-date scientific literature supporting vaccination against pertussis in pregnancy and outstanding scientific questions. Herein, we review the current and historically published literature and summarize the findings as consensus statements on vaccination against pertussis in pregnancy on behalf of the Global Pertussis Initiative.
Global Pertussis Initiative, immunity, pertussis, pregnancy, protection, vaccination
Jones, Christine E
48229079-8b58-4dcb-8374-d9481fe7b426
Abu-Raya, Bahaa
e6d7de89-5f0f-483f-82fd-73cf7d64213a
Forsyth, Kevin
ac663141-ed20-4a52-a55c-b0a05845bf65
Helperin, Scott A.
ac68f93c-6f8e-4359-811c-970e53f6e06d
Maertens, Kirsten
273ed12f-faf8-47e7-8330-a91a286312da
Jones, Chistine E.
c97530dd-39c8-4549-95b2-bc3e2eda9d47
Heininger, Ulrich
7d068d28-c550-4df6-b823-c3b53c567dfe
Hozbor, Daniela
90944999-00a4-46ef-b605-5961dbe6401e
Heinz Wirsing von König, Carl
8ed2481e-4967-4da9-9ca5-81fed38e86f2
Chitkara, Amar J.
ca1e17c9-ec9b-486c-b4d0-68a369affe80
December 2022
Jones, Christine E
48229079-8b58-4dcb-8374-d9481fe7b426
Abu-Raya, Bahaa
e6d7de89-5f0f-483f-82fd-73cf7d64213a
Forsyth, Kevin
ac663141-ed20-4a52-a55c-b0a05845bf65
Helperin, Scott A.
ac68f93c-6f8e-4359-811c-970e53f6e06d
Maertens, Kirsten
273ed12f-faf8-47e7-8330-a91a286312da
Jones, Chistine E.
c97530dd-39c8-4549-95b2-bc3e2eda9d47
Heininger, Ulrich
7d068d28-c550-4df6-b823-c3b53c567dfe
Hozbor, Daniela
90944999-00a4-46ef-b605-5961dbe6401e
Heinz Wirsing von König, Carl
8ed2481e-4967-4da9-9ca5-81fed38e86f2
Chitkara, Amar J.
ca1e17c9-ec9b-486c-b4d0-68a369affe80
Jones, Christine E, Abu-Raya, Bahaa, Forsyth, Kevin, Helperin, Scott A., Maertens, Kirsten, Jones, Chistine E., Heininger, Ulrich, Hozbor, Daniela, Heinz Wirsing von König, Carl and Chitkara, Amar J.
(2022)
Vaccination in pregnancy against pertussis: A consensus statement on behalf of the global pertussis initiative.
Vaccines, 10 (12), [1990].
(doi:10.3390/vaccines10121990).
Abstract
Vaccination against pertussis in pregnancy is safe for pregnant women and newborns. Vaccination against pertussis during the second or early third trimester of pregnancy is highly protective against pertussis in young infants. Vaccination early in the third trimester versus vaccination late in the third trimester is associated with higher newborn anti-B. pertussis antibody levels. Infants whose mothers were vaccinated in pregnancy have less boosting of anti-B. pertussis antibody concentrations after their own vaccination, but this is not clinically significant. More immunogenicity and vaccine effectiveness studies are needed in countries using whole-cell pertussis vaccines. Vaccination in pregnancy induces anti-B. pertussis antibodies in breast milk. COVID-19 mitigation strategies have resulted in a significant decrease in B. pertussis circulation, which could negatively affect population immunity against B. pertussis. Highlights: Infants are at high risk for severe morbidity and mortality from pertussis disease during early infancy. Vaccination against pertussis in pregnancy has emerged as the ideal strategy to protect infants during these early, vulnerable, first months of life. On 30 November and 1 December 2021, the Global Pertussis Initiative held a meeting that aimed to discuss and review the most up-to-date scientific literature supporting vaccination against pertussis in pregnancy and outstanding scientific questions. Herein, we review the current and historically published literature and summarize the findings as consensus statements on vaccination against pertussis in pregnancy on behalf of the Global Pertussis Initiative.
Text
vaccines-10-01990-v2
- Version of Record
More information
Published date: December 2022
Additional Information:
Funding Information:
The Global Pertussis Initiative is supported by Sanofi. It was established in 2001 to evaluate the ongoing pertussis challenges across the globe and recommend appropriate pertussis control strategies. Sanofi continues to fund this important initiative to provide a forum for scientific-, clinical-, and policy-based discussions. The views and opinions expressed in this publication, which could include the usage of Sanofi products that are inconsistent with the current labeling or licensed indication, are solely those of the authors and do not reflect the position of Sanofi. BA was funded by Michael Smith Health Research BC.
Funding Information:
The authors are scientific experts and, as such, received honoraria for their participation in this live meeting from Sanofi. In addition, Heininger, U., was a member of the Collaboration of European Experts on Pertussis Awareness Generation (CEEPAG; he was a group member until 2021), and he has received honoraria for participation in previously associated live meetings from Sanofi, USA and Sanofi, France, respectively, as well as receiving honoraria for educational activities from Pfizer, MSD, and InfectoPharm. Forsyth, K., and Chitkara, A.J., have also previously received honoraria from Sanofi. Tan, T.Q., has received grants from Merck and Sanofi and personal fees from GSK Biologicals and Sanofi, and honoraria from Sanofi. Wirsing von König, C.H., has received honoraria for attending meetings sponsored by Sanofi, GSK Biologicals SA, MSD, and Novartis Vaccines. Halperin, S.A., has received contracts for clinical trials and served on ad hoc advisory boards for Sanofi and GSK. Muloiwa, R., has received honoraria for educational activities from MSD and Sanofi. The authors declare no other conflict of interest.
Publisher Copyright:
© 2022 by the authors.
Keywords:
Global Pertussis Initiative, immunity, pertussis, pregnancy, protection, vaccination
Identifiers
Local EPrints ID: 473059
URI: http://eprints.soton.ac.uk/id/eprint/473059
ISSN: 2076-393X
PURE UUID: 47b2e101-a4c2-4655-8ddd-dc2f54b8cfc1
Catalogue record
Date deposited: 09 Jan 2023 18:42
Last modified: 17 Mar 2024 03:45
Export record
Altmetrics
Contributors
Author:
Bahaa Abu-Raya
Author:
Kevin Forsyth
Author:
Scott A. Helperin
Author:
Kirsten Maertens
Author:
Chistine E. Jones
Author:
Ulrich Heininger
Author:
Daniela Hozbor
Author:
Carl Heinz Wirsing von König
Author:
Amar J. Chitkara
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
